This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    MOR208C115
Previous Study | Return to List | Next Study

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (MINDway)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05222555
Recruitment Status : Recruiting
First Posted : February 3, 2022
Last Update Posted : November 24, 2023
Sponsor:
Information provided by (Responsible Party):
MorphoSys AG

Brief Summary:
This is an open-label, multicentre study too Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) who have had at least one, but no more than three prior systemic regimens and who are not eligible for high dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) at the time of study entry.

Condition or disease Intervention/treatment Phase
Diffuse Large B Cell Lymphoma Drug: Tafasitamab Drug: Lenalidomide Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 51 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Actual Study Start Date : July 19, 2022
Estimated Primary Completion Date : November 30, 2024
Estimated Study Completion Date : October 31, 2027


Arm Intervention/treatment
Experimental: Treatment (Tafasitamab + Lenalidomide)

Treatment:

Tafasitamab will be combined with lenalidomide in R/R DLBCL patients.

Dose:

Cohort 1: The dose of tafasitamab will be level 1 high dose in combination with the approved dose

Cohort 2: The dose of tafasitamab will be level 2 high dose in combination with the approved dose

Expansion Cohort: The dose of tafasitamab will be the dose that is deemed safe and tolerable as determined from cohort 1 & cohort 2

Treatment consisting of tafasitamab and lenalidomide combination will be administered until disease progression, unacceptable toxicity, or discontinuation for any other reason, whichever comes first. Lenalidomide can be given for up to 12 cycles in total, after which patients can continue with tafasitamab as monotherapy until progression or unacceptable toxicity.

Drug: Tafasitamab
tafasitamab will be administered intravenously at protocol defined timepoints
Other Names:
  • INCMOR00208
  • MOR00208
  • Xmab5574

Drug: Lenalidomide
lenalidomide will be administered orally at protocol defined timepoints




Primary Outcome Measures :
  1. Evaluate safety and tolerability [ Time Frame: 1 - 3 years approximately ]
    Incidence and severity of TEAEs

  2. Determine recommended dose [ Time Frame: 1 - 3 years approximately ]
    Incidence and severity of TEAEs combination with lenalidomide in R/R DLBCL patients


Secondary Outcome Measures :
  1. Evaluate pharmacokinetic profile [ Time Frame: Upto 1 year ]
    Tafasitamab serum concentration (Ctrough)

  2. Evaluate pharmacokinetic profile [ Time Frame: Upto 3 months ]
    Tafasitamab serum concentration (Cmax)

  3. Assess anti-tumor activity [ Time Frame: upto 1 year ]
    Number of participants with Best Objective Response Rate, ORR = complete response [CR] + partial response [PR]; by Investigator assessment based on Cheson et al (2007)

  4. Duration of response (DoR) [ Time Frame: 1 - 3 years approximatey ]
    Investigator assessment

  5. Progression-free Survival (PFS) [ Time Frame: 1 - 3 years approximately ]
    Investigator assessment


Other Outcome Measures:
  1. B cell numbers [ Time Frame: upto 1 year ]
    Absolute counts and percentage change from baseline in measurement of B cell numbers in peripheral blood

  2. T cell numbers [ Time Frame: upto 1 year ]
    Absolute counts and percentage change from baseline in measurement of T cell numbers in peripheral blood

  3. NK cell numbers [ Time Frame: upto 1 year ]
    Absolute counts and percentage change from baseline in measurement of NK cell numbers in peripheral blood



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Major Inclusion Criteria:

  1. Capable of giving signed informed consent
  2. Age 18 years or older
  3. Histologically confirmed diagnosis of DLBCL
  4. Tumor tissue for retrospective central pathology review must be provided as an adjunct to participation in this study.
  5. Patients must have:

    • relapsed and/or refractory disease
    • at least one bidimensionally measurable, PET positive disease site (transverse diameter of ≥1.5 cm and perpendicular diameter of ≥1.0 cm at baseline)
    • received at least one, but no more than three previous systemic regimens for the treatment of DLBCL and one therapy line must have included a CD20-targeted therapy
    • Eastern Cooperative Oncology Group 0 to 2
  6. Patients not considered in the opinion of the investigator eligible to undergo intensive salvage therapy including ASCT
  7. Patients must meet the following laboratory criteria at screening:

    • absolute neutrophil count ≥1.5 × 10^9/L
    • platelet count ≥90 × 10^9/L
    • total serum bilirubin ≤2.5 × ULN or ≤5 × ULN in cases of Glibert's Syndrome or liver involvement by lymphoma
    • alanine transaminase, aspartate aminotransferase and alkaline phosphatase ≤3 × ULN or <5 × ULN in cases of liver involvement
    • serum creatinine clearance ≥ 60 mL/minute
  8. Patients who received previous CD19 targeted therapy (other than tafasitamab) must have CD19 positive lymphoma confirmed on a biopsy taken since completing the prior CD19 targeted therapy
  9. Patients with primary refractory disease who received at least one, but no more than three previous systemic regimens (including a CD20 targeted therapy)

Major Exclusion Criteria:

  1. Patients who are legally institutionalized or concurrent enrollment in another interventional clinical study
  2. Patients who have:

    • other histological type of lymphoma
    • a history of "double/triple hit" genetics
  3. Patients who have, within 14 days prior to Day 1 dosing:

    • not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy
    • undergone major surgery (with 4 weeks) or suffered from significant traumatic injury
    • received live vaccines (within 4 weeks).
    • required parenteral antimicrobial therapy for active, intercurrent infections
  4. Patients who:

    • have not recovered sufficiently from the adverse toxic effects of prior therapies
    • were previously treated with IMiDs® (e.g. thalidomide, LEN)
    • have history of hyper sensitivity to compounds of similar biological or chemical composition to tafasitamab IMiDs® and/or the excipients contained in the study treatment formulations
    • have undergone ASCT within the period ≤ 3 months prior to signing the informed consent form.
    • have undergone previous allogenic stem cell transplantation
    • have a history of deep venous thrombosis/embolism and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period
    • concurrently use other anticancer or experimental treatments
  5. History of other malignancy that could affect compliance with the protocol or interpretation of results. Exceptions

    • Patients with any malignancy appropriately treated with curative intent and the malignancy has been in remission without treatment for >2 years prior to enrollment are eligible
    • Patients with low-grade, early-stage prostate cancer (Gleason score 6 or below, Stage 1 or 2) with no requirement for therapy at any time prior to study are eligible
  6. Patients with:

    • positive hepatitis B and/or C serology.
    • known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV)
    • CNS lymphoma involvement
    • history or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that would in the investigator's opinion preclude participation in the study or compromise the patient's ability to give informed consent
    • history or evidence of rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
    • gastrointestinal (GI) abnormalities (issue with absorption) including the inability to take oral medication
    • history or evidence of severe hepatic impairment (total serum bilirubin > 3mg/dL), jaundice unless secondary to Gilbert's syndrome or documented liver involvement by lymphoma
    • history of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical class
    • any other medical condition which, in the investigator's opinion, makes the patient unsuitable for the study
  7. Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and refrain from breast feeding and donating eggs; agreement to ongoing pregnancy testing during the course of the study, and after study therapy has ended Male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom and agreement to refrain from donating sperm

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05222555


Contacts
Layout table for location contacts
Contact: Medical Information +1 844 667-1992 medinfo@morphosys.com

Locations
Show Show 62 study locations
Sponsors and Collaborators
MorphoSys AG
Layout table for additonal information
Responsible Party: MorphoSys AG
ClinicalTrials.gov Identifier: NCT05222555    
Other Study ID Numbers: MOR208C115
First Posted: February 3, 2022    Key Record Dates
Last Update Posted: November 24, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MorphoSys AG:
monoclonal antibody
CD19
tafasitamab
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Lenalidomide
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents